A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

Mario F. Fraga, Esteban Ballestar, Ana Villar‐Garea et al. · Nature Genetics · 2005 · 1.9K citations

Histone Modifications, Tumor Biology, Chromatin +12

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

Owen A. O’Connor, Steven M. Horwitz, Tamás Masszi et al. · Journal of Clinical Oncology · 2015 · 527 citations · Full text

Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.

Jane A. Plumb, Paul W. Finn, Robert J. Williams et al. · PubMed · 2003 · 313 citations

Histone Modifications, Colon Tumor Xenografts, Chemoprevention Strategy +18

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Nicholas Mitsiades, Constantine S. Mitsiades, Paul G. Richardson et al. · Blood · 2003 · 293 citations

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

Nicola Steele, Jane A. Plumb, Laura Vidal et al. · Clinical Cancer Research · 2008 · 239 citations · Full text